Also presented at this congress:
Oral Presentation:
Zolbetuximab + mFOLFOX6 as 1L treatment for patients with CLDN18.2+/ HER2 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from SPOTLIGHT
Authors: Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu R-H, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Ajani JA
This file is not available. Please refer to the congress platform: https://conferences.asco.org/gi/attend